FindTrial
Sign In

Open Label Randomized trial of Colchicine, Aspirin and Montelukast in Covid-19

Open Label Randomized trial of Colchicine, Aspirin and Montelukast for prevention of Adult Multisystem Inflammatory Syndrome in SARS-CoV-2 patients - CAM-Covid-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/028088
Enrollment
34
Registered
2020-09-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J128- Other viral pneumonia

Interventions

Intervention1: Colchicine, Aspirin and Montelukast: Intervention: The intervention arm will receive, in addition to the standard of care, the following drugs: Colchicine - 0.6 mg per oral, 12 hourly

Sponsors

Vivek Chauhan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of SARS-CoV-2 admitted in our tertiary care hospital in Shimla with an oxygen saturation of <90% on room air

Exclusion criteria

Exclusion criteria: o Patients unwilling to provide consent for the drug regimen. o Patients who die within 48 hours of admission in our hospital. o Patients having GFR

Design outcomes

Primary

MeasureTime frame
Primary Outcome: Change in the marker of Adult Multi-system Inflammatory Syndrome i.e. C-reactive Protein Secondary Outcomes: Change in other markers of AMIS (Ferritin, D-dimer), Need for Ventilation (invasive or non-invasive), Mortality, Duration of Hospital Stay, Change in CT severity score at 1 month. Timepoint: 4 month—

Secondary

MeasureTime frame
Secondary Outcomes: Change in other markers of AMIS (Ferritin, D-dimer), Need for Ventilation (invasive or non-invasive), Mortality, Duration of Hospital Stay, Change in CT severity score at 1 month. Timepoint: 3 month—

Countries

India

Contacts

Public ContactVivek Chauhan

IGMC Shimla

drvivekshimla@yahoo.com9418341202

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026